CAS 149629-70-9

Impentamine dihydrobromide

CAS : 149629-70-9

Impentamine dihydrobromide (IMB) is a research and development drug product that has been synthesized for the treatment of epilepsy. IMB is an impurity standard for impentamine, a synthetic drug that inhibits the enzyme acetylcholinesterase and has been shown to be effective in the treatment of Alzheimer's disease. Impentamine dihydrobromide is a metabolite of impentamine, which inhibits the enzyme acetylcholinesterase and has been shown to be effective in the treatment of Alzheimer's disease. Impentamine dihydrobromide binds to acetylcholinesterase by competitive inhibition and causes an accumulation of acetylcholine in the synaptic cleft. This accumulation leads to increased neurotransmission at nerve terminals, because acetylcholine is necessary for neurotransmitter release.

Formule : C₈H₁₇Br₂N₃

Degré de pureté : Min. 95%

Masse moléculaire : 315.05 g/mol

Ref: 3D-ZFA62970

Impentamine dihydrobromide

CAS : 149629-70-9

Impentamine dihydrobromide is a histamine H3 receptor antagonist.

Formule : C₈H₁₇Br₂N₃

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 315.05

Ref: TM-T22866